A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Multiple Dose Regimens of CHF 5074 for up to 2 Years on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Multiple Dose Regimens of CHF 5074 for up to 2 Years on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2015

At a glance

  • Drugs CHF 5074 (Primary)
  • Indications Mild cognitive impairment
  • Focus Therapeutic Use
  • Sponsors CereSpir; Chiesi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Dec 2012 New trial record
    • 21 Nov 2012 Status changed from not yet recruiting to withdrawn prior to recruitment according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top